The Pfizer Vaccines US Medical Affairs Team invites you to attend an educational webinar series. It is designed to communicate scientific information which may include recent study results to inform healthcare providers regarding Pfizer's RSV vaccine.
The webinar series will include a live question-and-answer session with Pfizer medical experts.
We will soon be hosting a Ready for RSV session
If you would like to be notified when the registration opens for the next webinar,
click hereTo view recordings of previous Ready for RSV webinars
click hereIntended Audience: US healthcare professionals including but not limited to physicians, nurse practitioners, pharmacists, and physician assistants.
Continuing medical education credit is NOT associated with this event.
Active immunization of pregnant individuals at 32 through 36 weeks gestational age for the prevention of lower respiratory tract disease (LRTD) and severe LRTD caused by respiratory syncytial virus (RSV) in infants from birth through 6 months of age.
Active immunization for the prevention of LRTD caused by RSV in individuals 60 years of age and older.
Active immunization for the prevention of LRTD caused by RSV in individuals 18 through 59 years of age who are at increased risk for LRTD caused by RSV.
WEBINAR INFO
New approved indication for Pfizer’s RSV Vaccine
RSV burden of disease in adults 18-59 years of age
Safety & Immunogenicity of RSVPreF in adults 18-59 years of age at increased risk for lower respiratory tract disease from RSV
Intended Audience: US healthcare professionals including but not limited to physicians, nurse practitioners, pharmacists, and physician assistants.
Continuing medical education credit is NOT associated with this event.
There are no available videos at this time.
Please try again later.